Sustainable Companies for the 21st Century Evolution of the Components of Sustainability for GlaxoSmithKline Dr. James Hagan Vice President Corporate Environment, Health & Safety April 23, 2002
2 GSK 100,000 People 120 Countries 105 Manufacturing Sites 23 R&D Sites $29.5 Billion in Sales
3 GSK Products Pharmaceuticals: Antibiotics, Anti-Depressants, AIDS, Diabetes, Respiratory, Vaccines Consumer: Aquafresh, Tums, Nicorette, Lucozade, Horlicks
4 SUSTAINABILITY Environment Social Financial
5 Compliance Strict Legal Compliance Liability Avoidance Ethical Considerations Competitive Advantage
6 Regulations Command & Control Technology Driven Standards Driven Risk Based Transparency
7 Environmental Measurement Gross Measures - Visible Pollution Parts per Million Parts per Billion Parts per Trillion Molecular Analysis
8 SCOPE Local National Global
9 Waste Management Treatment/Disposal of Waste Recovery/Recycle Process Changes to Minimize/Eliminate Waste
10 Natural Resources Process Efficiency Renewable Resources Natural Environmental Cycles
11 Sustainability Reporting Company Confidential Respond to requests Annual Report Statement Separate Environmental Report Separate Social & Environment Report Triple Bottom Line Report – Financial, Social, Environmental
12 Internal Control Local Management Senior Management Concern Audit Committee of the Board CSR Committee of the Board
13 External Stakeholders Confrontation Stand-off One-way Communication Dialogue Stakeholder Groups - Dialogue on a range of issues
14 Social Responsibility Corporate Philanthropy - wide view Corporate Philanthropy - aligned with Business Integral to Business - Access to Medicines Integral to R&D - Developing Country Diseases Partnerships with Stakeholders
15 Discover medicines for conventional diseases Provide medicines for developing countries Discover medicines for developing countries Tailor medicines based on genetic make-up Innovative “Manufacturing” Approaches Business Sustainability